LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET plus ) NSCLC.

被引：0
作者：
Goldman, Jonathan W.
Sands, Jacob
Hallqvist, Andreas
Kim, Hye Ryun
Li, Guoping
Wu, Lin
Su, Weiji
Bayt, Theresa
Yang, Xue-Ning
Hochmair, Maximilian
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Sahlgrens Univ Hosp, Inst Clin Sci, Dept Oncol, Gothenburg, Sweden
[4] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[5] Third Peoples Hosp Chengdu, Chengdu Inst Resp Hlth, Branch Natl Clin Res Ctr Resp Dis, Chengdu, Peoples R China
[6] Hunan Canc Hosp, Thorac Internal Med Oncol Dept, Changsha, Hunan, Peoples R China
[7] Eli Lilly & Co, Indianapolis, IN USA
[8] Eil Lilly & Co, Indianapolis, IN USA
[9] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[10] Klin Floridsdorf, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8115
引用
收藏
页数：1
相关论文
共 50 条
[41]   IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC [J].
Felip, E. ;
Vallieres, E. ;
Zhou, C. ;
Wakelee, H. ;
Bondarenko, I. ;
Sakai, H. ;
Saito, H. ;
Ursol, G. ;
Kawaguchi, K. ;
Liu, Y. ;
Levchenko, E. ;
Kislov, N. ;
Reck, M. ;
Liersch, R. ;
McNally, V. A. ;
Zhu, Q. ;
Ding, B. ;
Bennett, E. ;
Gitlitz, B. ;
Altorki, N. K. .
ANNALS OF ONCOLOGY, 2021, 32 :S1319-S1319
[42]   IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC [J].
Wang, Jie ;
Fan, Yun ;
Fang, Jian ;
He, Jianxing ;
Liu, Yunpeng ;
Tao, Min ;
Altorki, Nasser ;
Felip, Enriqueta ;
Wakelee, Heather ;
Vallieres, Eric ;
Belleli, Rossella ;
McNally, Virginia ;
Bennett, Elizabeth ;
Gitlitz, Barbara J. ;
Zhou, Caicun .
CANCER RESEARCH, 2024, 84 (07)
[43]   A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result. [J].
Jie, H. ;
Xiangru, Z. ;
Han, B. ;
Liu, Y. ;
Wang, Q. ;
Xu, S. ;
Sheng, Y. ;
Li, Q. ;
Wu, S. ;
Chen, C. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[44]   IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC [J].
Zhou, C. ;
Das Thakur, M. ;
Srivastava, M. K. ;
Zou, W. ;
Xu, H. ;
Ballinger, M. ;
Felip, E. ;
Wakelee, H. ;
Altorki, N. K. ;
Reck, M. ;
Liersch, R. ;
Kryzhanivska, A. ;
Harada, M. ;
Tanaka, H. ;
Hamm, J. ;
McCune, S. ;
McNally, V. ;
Bennett, E. ;
Gitlitz, B. ;
Novello, S. .
ANNALS OF ONCOLOGY, 2021, 32 :S1374-S1374
[45]   A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. [J].
Kelly, Karen ;
Altorki, Nasser K. ;
Eberhardt, Wilfried Ernst Erich ;
O'Brien, Mary E. R. ;
Spigel, David R. ;
Crino, Lucio ;
Tsai, Chun-Ming ;
Kim, Joo-Hang ;
Cho, Eun Kyung ;
Szczesna, Aleksandra ;
Burghuber, Otto ;
Hoffman, Philip C. ;
Keshavjee, Shaf ;
Orlov, Sergey ;
Serwatowski, Piotr ;
Wang, Jiuzhou ;
Foley, Margaret A. ;
Horan, Julie D. ;
Park, Jung Wook ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[46]   ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB IIIA anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC). [J].
Solomon, Benjamin J. ;
Ahn, Jin Seok ;
Barlesi, Fabrice ;
Dziadziuszko, Rafal ;
Nishio, Makoto ;
Shaw, Alice Tsang ;
Bordogna, Walter ;
Meyenberg, Christoph ;
Wu, Yi-Long .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[47]   IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). [J].
Wakelee, Heather A. ;
Altorki, Nasser K. ;
Zhou, Caicun ;
Csoszi, Tibor ;
Vynnychenko, Ihor O. ;
Goloborodko, Oleksandr ;
Luft, Alexander ;
Akopov, Andrey ;
Martinez-Marti, Alex ;
Kenmotsu, Hirotsugu ;
Chen, Yuh-Min ;
Chella, Antonio ;
Sugawara, Shunichi ;
Gitlitz, Barbara J. ;
Bennett, Elizabeth ;
Wu, Fan ;
Yi, Jing ;
Deng, Yu ;
McCleland, Mark ;
Felip, Enriqueta .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48]   Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR plus NSCLC. [J].
Yue, Dongsheng ;
Xu, Shi-Dong ;
Wang, Qun ;
Li, Xiaofei ;
Shen, Yi ;
Zhao, Heng ;
Chen, Chun ;
Mao, Weimin ;
Liu, Wei ;
Liu, Junfeng ;
Zhang, Lan-Jun ;
Ma, Haitao ;
Li, Qiang ;
Yang, Yue ;
Liu, Yongyu ;
Chen, Haiquan ;
Zhang, Zhenfa ;
Zhang, Bin ;
Gong, Fuyu ;
Wang, Changli .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49]   KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. [J].
Wakelee, Heather A. ;
Liberman, Moishe ;
Kato, Terufumi ;
Tsuboi, Masahiro ;
Lee, Se-Hoon ;
He, Jie ;
Gao, Shugeng ;
Chen, Ke-Neng ;
Dooms, Christophe Alfons ;
Majem, Margarita ;
Eigendorff, Ekkehard ;
Martinengo, Gaston Lucas ;
Bylicki, Olivier ;
Rodriguez-Abreu, Delvys ;
Chaft, Jamie E. ;
Novello, Silvia ;
Yang, Jing ;
Keller, Steven M. ;
Samkari, Ayman ;
Spicer, Jonathan .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[50]   MAGE-A3 GENE EXPRESSION FREQUENCY AND DEMOGRAPHY DATA OF STAGE IB-IIIA NSCLC PATIENTS FROM ONGOING MAGRIT PHASE III TRIAL EVALUATING MAGE-A3 ANTIGEN SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT [J].
Kim, J. H. ;
Jassem, J. ;
Tada, H. ;
Yoshimura, M. ;
Piantedosi, F. ;
Zatloukal, P. ;
Krakorova, G. ;
Debois, M. ;
Debruyne, C. ;
Vansteenkiste, J. .
ANNALS OF ONCOLOGY, 2010, 21 :134-134
12345